Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Common Equity (2016 - 2025)

Sanofi's Common Equity history spans 17 years, with the latest figure at $83.1 billion for Q4 2025.

  • On a quarterly basis, Common Equity changed 0.32% to $83.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $83.1 billion, a 0.32% change, with the full-year FY2025 number at $83.1 billion, changed 0.32% from a year prior.
  • Common Equity hit $83.1 billion in Q4 2025 for Sanofi, up from $79.6 billion in the prior quarter.
  • Over the last five years, Common Equity for SNY hit a ceiling of $83.1 billion in Q4 2025 and a floor of $76.1 billion in Q2 2022.
  • Historically, Common Equity has averaged $79.0 billion across 5 years, with a median of $79.0 billion in 2024.
  • Biggest five-year swings in Common Equity: increased 9.12% in 2021 and later decreased 2.89% in 2022.
  • Tracing SNY's Common Equity over 5 years: stood at $78.6 billion in 2021, then fell by 2.89% to $76.3 billion in 2022, then increased by 4.41% to $79.7 billion in 2023, then rose by 3.97% to $82.8 billion in 2024, then rose by 0.32% to $83.1 billion in 2025.
  • Business Quant data shows Common Equity for SNY at $83.1 billion in Q4 2025, $79.6 billion in Q2 2025, and $82.8 billion in Q4 2024.